ArticleJACC. Case reports2025
Percutaneous Closure of Residual Shunt After Patent Foramen Ovale Closure With a Biodegradable Occluder.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundResidual right-to-left shunt (RLS) after patent foramen ovale (PFO) closure may lead to recurrent stroke or migraine. Conventional metallic occluders often entail shortcomings, including suboptimal conformability and permanent metal implantation. Biodegradable occluders offer potential advantages through enhanced compatibility and gradual resorption. CASE SUMMARY: A 52-year-old woman who developed recurrent cerebral infarction and migraine 20 months after PFO closure was diagnosed with a residual RLS, which was subsequently successfully treated using a biodegradable PFO occluder. DISCUSSION: We herein report a successful case of residual RLS management using a biodegradable PFO occluder, offering a novel therapeutic strategy for the treatment of residual shunts after PFO closure. NOVELTY: To our knowledge, this is the first reported case demonstrating the successful clinical application of a biodegradable PFO occluder for the transcatheter closure of residual shunt after initial PFO closure. TAKE-HOME MESSAGE: This case highlights the feasibility and efficacy of a biodegradable device for managing residual shunt, providing a novel therapeutic option in selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.